Resveratrol enhances the suppressive effects of arsenic trioxide on primitive leukemic progenitors.

Abstract

Efforts to enhance the antileukemic properties of arsenic trioxide are clinically relevant and may lead to the development of new therapeutic approaches for the management of certain hematological malignancies. We provide evidence that concomitant treatment of acute myeloid leukemia (AML) cells or chronic myeloid leukemia (CML) cells with resveratrol potentiates arsenic trioxide-dependent induction of apoptosis. Importantly, clonogenic assays in methylcellulose demonstrate potent suppressive effects of the combination of these agents on primitive leukemic progenitors derived from patients with AML or CML. Taken together, these findings suggest that combinations of arsenic trioxide with resveratrol may provide an approach for targeting of early leukemic precursors and, possibly, leukemia initiating stem cells.

• Authors: Edward J Wu, Dennis J Goussetis, Elspeth Beauchamp, Ewa M Kosciuczuk, Jessica K Altman, Elizabeth A Eklund, Leonidas C Platanias
• Journal: Cancer biology & therapy (Cancer Biol Ther) Vol. 15 Issue 4 Pg. 473-8 (Apr 2014) ISSN: 1555-8576 [Electronic] United States
• PMID: 24496081 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, U.S. Gov't, Non-P.H.S.)

Chemical References

• Antineoplastic Agents
• Arsenicals
• Oxides
• Stilbenes
• Resveratrol
• Arsenic Trioxide

Topics

• Antineoplastic Agents (pharmacology)
• Apoptosis (drug effects)
• Arsenic Trioxide
• Arsenicals (pharmacology)
• Autophagy (drug effects)
• Cell Line, Tumor
• Drug Synergism
• Humans
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive (metabolism, pathology)
• Leukemia, Myeloid, Acute (metabolism, pathology)
• Neoplastic Stem Cells (drug effects, pathology)
• Oxides (pharmacology)
• Resveratrol
• Stilbenes (pharmacology)